Treatment of High-Risk Venous Thromboembolism

Expert Panelist Lead: David Paje, MD, FACP, SFHM

Accreditation and Designation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Blackwell Futura Media Services and the Society of Hospital Medicine Blackwell Futura Media Services is accredited by the ACCME to provide continuing medical education for physicians.”

Blackwell Futura Media Services designates this enduring material for a maximum of (1 CREDIT) AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. 

Educational Objectives

Upon completion of this educational activity, participants will be better able to: 

  • Deliver a more cost effective evaluation for VTE.
  • Better assess low and high risk VTE patients.
  • Better understand VTE treatment methods and reversals
Series

Activity 1- A Cost-Effective Approach to VTE Diagnosis

Activity 2- Treatment of Low-Risk Venous Thromboembolism

Activity 3- Treatment of High-Risk Venous Thromboembolism

Activity 4- Improving the Safety of Anticoagulation with DOACs

Instructions on Receiving Credit

This activity is intended for physicians. For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.

Physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity during the valid credit period, which is up to two years from initial publication. 

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-physician
Course opens: 
06/01/2016
Course expires: 
06/01/2019
Non-member cost:
$0.00
Parent activity set: 
Rating: 
0
Activity Disclosures

This activity is supported by an educational grant from Janssen Pharmaceutical, Inc.

Allison Burnett, PharmD, PhC, CACP- University of New Mexico Hospital-

  • Advisory Committee/Board
    • Anticoagulation Forum Board Member

Steve Deitelzweig, MD, MMM, SFHM, FACP- Ochsner Health System-

  • Advisory Committee/Board
    • Janssen
  • Speaker Bureau, Faculty, Peer Reviewer
    • Bristol Myer Squibb/Pfizer
    • Janssen
  • Research Grants/Contracts
    • Janssen

Andrew Dunn, MD, MPH, FACP, SFHM- Mount Sinai Health System-

  • Research Grants/Contracts
    • Bristol Myer Squibb/Pfizer

Scott Kaatz DO, MSc, FACP, SFHM- Hurley Medical Center

  • Consultant
    • Janssen
  • Advisory Committee/Board
    • Boehring Ingelheim
    • Bristol Myer Squibb/Pfizer
    • Janssen
    • Daiichi Sankyo
    • Portola
  • Speaker Bureau, Faculty, Peer Reviewer
    • Boehring Ingelheim
    • Bristol Myer Squibb/Pfizer
    • Janssen
    • Daiichi Sankyo
    • CSL Behring

David G. Paje, MD, FACP, SFHM- VA Ann Arbor Healthcare System- has no conflicts of interest to disclose

Charles Pollack, MA, MD, FACEP- Thomas Jefferson University-

  • Consultant
    • Boehring Ingelheim
    • Janssen
    • Bristol Myer Squibb/Pfizer
    • Daiichi Sankyo

SHM complies with ACCME Standards for Commercial Support by following policies and procedures designed to identify and manage conflicts of interest in Company-supported Society CME programs at all stages in program design and implementation. All programs are developed independent of any sponsor input and do not allow the use of trade names. Furthermore, SHM instructs faculty to present a balanced view of treatment options and reviews material to make sure this is the case. SHM is transparent about all funding received.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
06/01/2016
Course expires: 
06/01/2019

Price

Non-member cost:
$0.00
Please login or register to take this course.